This week, we launched our “Conversations” forum as part of our larger goal of engaging a broad spectrum of thinkers, patient advocates, providers and manufacturers on their thoughts about pressing health care questions.
More than 9,600 websites that illegally sell potentially dangerous, counterfeit drugs to patients were targeted this week by a partnership that included INTERPOL, the FDA, international regulatory and law enforcement bodies, as well as pharmaceutical companies.
As communities across the country celebrate June as National LGBT Pride Month, it is important to acknowledge the unique health challenges facing the LGBT community. In an effort to better understand and address these challenges, the National Health Interview Survey for 2013 will include questions specifically related to the LGBT population.
Recently the American Medial Association endorsed recognizing obesity as a disease. The U.S.
Today, Rep. Terry (R. NE) chairman of the House Energy and Commerce Subcommittee on Commerce, Manufacturing and Trade held a hearing to highlight how India’s industrial policy is hurting U.S.
The Partnership to Fight Chronic Disease (PFCD) has released a thoughtful new policy paper outlining the most effective ways to lower Medicaid health care costs without compromising quality of care or patient health outcomes.
In a previous post, I shared my personal experience with stroke and encouraged readers to know the warning signs and symptoms of stroke. A new report by PhRMA on Medicines in Development for Heart Disease and Stroke provides
As our President and CEO John Castellani emphasized, “Healthy debate is the foundation of progress and advancement.” This is something we feel very strongly about, and the initiatives announced this week show our commitment to being part of the ongoing dialogue around health care.
Dean Kamen, a great scientist and inventor, said that “we now live in a world where technology, in many ways, has triumphed over death.” As we look at the bigger picture around the value of innovation, particularly in a cost-containment environment, we must always keep this triumph in the back of our minds.
Last week, POLITICO sat down with President and CEO John Castellani to discuss how he is working to elevate the biopharmaceutical industry’s role as a thought leader within the health care ecosystem, as well as a key player in policy discussions within Washington and beyond.
A new alliance was launched today to begin educating the public and policymakers about the growing imbalance with the United States’ trading relationship with India and the potential consequences for American job losses if these concerns are not addressed.
Inventor Thomas Edison once said, “If we did all the things we are capable of, we would literally astound ourselves.”
Last week, we took another step in our fight against chronic disease by extending our successful partnership with the Women in Government Foundation, Inc. (WIG), a national non-profit, non-partisan organization of women state legislators.
The first step toward finding solutions in our health care ecosystem is to identify what works, protect what is successful and fix what isn’t. This includes access to medicines, continued research and development and developing programs that get patients the treatments they need.
Craving some health policy news on a Friday afternoon? Check out an op-ed that ran in The Hill today from our CEO, John Castellani, on Part D.
Science has been on my mind lately – and for two very good reasons.
The Annals of Internal Medicine recently published a study that compared prescription diabetes medicine use between Medicare Part D and the Veterans Affairs (VA) program, specifically focusing on generic drug use. The study and subsequent media coverage overlook some important facts about prescription drug coverage in these two programs.
Every 39 seconds an American dies from cardiovascular disease, and more than 83 million Americans have at least one type of the disease, the American Heart Association (AHA) reports. But today, America’s biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death of Americans – heart disease and stroke.